Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP

Annals of Hematology

Volumn 89, Issue 8, 2010, Pages 783-787

  Samaras, Panagiotis ^a   Heider, Helen ^a   Haile, Sarah R ^b   Petrausch, Ulf ^a   Schaefer, Niklaus G ^a   Siciliano, Raffaele Daniele ^c   Meisel, Alexander ^a   Meisel, Axel ^a   Zweifel, Martin ^a   Knuth, Alexander ^a   Stenner Liewen, Frank ^a   Stenner Liewen, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Diffuse large B cell lymphoma; R CHOP; Rituximab; Statins; Survival

Indexed keywords

ATORVASTATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUINDOSTATIN; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PREDNISONE; RITUXIMAB; SIMVASTATIN; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG USE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC CAPACITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; DISEASE FREE SURVIVAL; DRUG INTERACTION; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 77954687871     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0926-0     Document Type: Article

References (26)

1. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
2. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
3. Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445
4. Winiarska M, Bil J, Wilczek E et al (2008) Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 5:e64
5. Goldstein MR, Mascitelli L, Pezzetta F (2009) Monoclonal antibody therapy and non-Hodgkin's lymphoma. N Engl J Med 360:192 (author reply 193)
6. Cragg MS (2008) The potential effect of statins on rituximab immunotherapy. PLoS Med 5:e77
7. Ennishi D, Asai H, Maeda Y et al. (2010) Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol (in press). doi:10.1093/annonc/mdp490
8. Nowakowski GS, Maurer MJ, Habermann TM et al (2010) Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 28:412-417
9. Hutchings M, Specht L (2008) PET/CT in the management of haematological malignancies. Eur J Haematol 80:369-380
10. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
11. Bland JM, Altman DG (2004) The logrank test. BMJ 328:1073
12. R Development Core Team (2009) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www. R-project.org
13. Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83:1165-1173
14. Dixon DO, Neilan B, Jones SE et al (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295-305
15. Bastion Y, Blay JY, Divine M et al (1997) Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 15:2945-2953
16. Petrausch U, Samaras P et al. (2010) Risk adapted FDG-PET/CTbased follow-up in patients with diffuse large B-cell lymphoma after first line therapy. Ann Oncol (in press). doi:10.1093/annonc/ mdq015
17. Li L, Sun J, Sun Y, He Z (2008) LC-ESI-MS determination of lovastatin in human plasma. Chromatographia 67:621-625
18. Davidson MH, Lukacsko P, Sun JX et al (2002) A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. Clin Ther 24:112-125
19. Cheung AK, DeVault GA Jr, Gregory MC (1993) A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 3:1884-1891
20. Guillen D, Cofan F, Ros E et al (2009) Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 394:1687-1696
21. Borek-Dohalsky V, Huclova J, Barrett B et al (2006) Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study. Anal Bioanal Chem 386:275-285
22. Hermann M, Christensen H, Reubsaet JL (2005) Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 382:1242-1249
23. Kantola T, Kivisto KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65
24. Katano H, Pesnicak L, Cohen JI (2004) Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 101:4960-4965
25. Issat T, Nowis D, Jakobisiak M, Golab J (2004) Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncol Rep 12:1371-1375
26. Ajith TA, Harikumar KB, Thasna H et al (2006) Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice. Clin Chim Acta 366:322-328